Braidwell LP Purchases New Holdings in Immunic, Inc. $IMUX

Braidwell LP acquired a new position in Immunic, Inc. (NASDAQ:IMUX) during the 2nd quarter, HoldingsChannel reports. The fund acquired 645,010 shares of the company’s stock, valued at approximately $9,914,000.

Several other large investors also recently bought and sold shares of the company. CTC Alternative Strategies Ltd. acquired a new position in shares of Immunic during the first quarter valued at approximately $27,000. ADAR1 Capital Management LLC acquired a new stake in shares of Immunic in the first quarter worth approximately $33,000. Qube Research & Technologies Ltd purchased a new stake in shares of Immunic during the third quarter worth approximately $29,000. Two Sigma Investments LP purchased a new stake in shares of Immunic during the third quarter worth approximately $52,000. Finally, Virtu Financial LLC acquired a new position in Immunic in the 3rd quarter valued at $99,000. 51.82% of the stock is currently owned by hedge funds and other institutional investors.

Immunic Price Performance

Shares of IMUX opened at $14.24 on Thursday. The firm has a 50-day simple moving average of $15.05 and a two-hundred day simple moving average of $12.94. The stock has a market cap of $194.23 million, a PE ratio of -3.25 and a beta of 1.41. Immunic, Inc. has a 1-year low of $5.06 and a 1-year high of $17.43.

Immunic (NASDAQ:IMUX) last issued its quarterly earnings data on Tuesday, August 11th. The company reported ($0.80) EPS for the quarter, topping the consensus estimate of ($1.16) by $0.36. As a group, sell-side analysts expect that Immunic, Inc. will post -3.88 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

IMUX has been the topic of a number of research reports. Roth Capital restated a “buy” rating on shares of Immunic in a report on Tuesday. B. Riley Financial dropped their target price on shares of Immunic from $40.00 to $27.00 and set a “buy” rating for the company in a report on Friday, May 22nd. Wedbush started coverage on shares of Immunic in a research report on Monday, August 17th. They issued an “outperform” rating and a $45.00 target price for the company. LADENBURG THALM/SH SH raised shares of Immunic to a “strong-buy” rating in a research note on Wednesday, July 29th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Immunic in a research note on Wednesday, August 26th. Three equities research analysts have rated the stock with a Strong Buy rating, seven have given a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Buy” and a consensus price target of $47.25.

Immunic Company Profile

Immunic, Inc is a clinical-stage biopharmaceutical company focused on developing novel oral therapies to treat chronic inflammatory and autoimmune diseases as well as certain cancers. The company’s research strategy centers on small-molecule immunology, aiming to offer targeted treatments with improved safety and tolerability profiles. By modulating key signaling pathways within the immune system, Immunic seeks to address underlying disease mechanisms and achieve durable therapeutic benefits for patients.

Immunic’s lead product candidate, vidofludimus calcium (IMU-838), is an oral selective dihydroorotate dehydrogenase (DHODH) inhibitor in Phase 2 clinical development for conditions including ulcerative colitis, Crohn’s disease and relapsing multiple sclerosis.